Draft Evidence Report
Midwest CEPAC

PDF cover

This is not the most recent version of this material.
For an updated version, please see the relevant topic page.

Atopic Dermatitis: Draft Evidence Report

A draft evidence report assessing the comparative clinical effectiveness and value of crisaborole (Eucrisa™, Pfizer, Inc.) and dupilumab (Dupixent®, Sanofi and Regeneron, Inc.) for treatment of atopic dermatitis. This report is open to public comment for four weeks until April 21st at 5pm CT. More information on submitting public comment is available here.


View All Materials on this Topic or Go Back to View More Materials